Our ADME-optimized subset features 120,000 drug-like screening compounds with predicted favorable ADME characteristics. It is distinctively focused on skin permeability, gastrointestinal absorption and blood-brain barrier penetration. Additionally, machine learning screening allowed us to select over 419,000 stock compounds to show reduced risk of CYP3A4, CYP2D6, and CYP2C9 inhibition, minimizing potential drug-drug interactions.

We offer 2,300 synthetically versatile fragments featuring structurally diverse poised scaffolds, selected proceeding from the concept of poised chemistry introduced by DSI and SGC for rapid analog synthesis, hit elaboration and SAR exploration in FBDD.

Explore 2,900 stock-available fragments featuring multiple synthetic vectors and high commercial availability of close analogs, facilitating fragment growing and hit-to-lead optimization.

Where innovative chemistry and chemically minded AI meet - unique products are born! We are proud to introduce the first-in-class dual EGFR/FGFR1 inhibitors designed and synthesized at Life Chemicals in collaboration with Variational AI. Evidently, the success of this project has demonstrated the power of AI-driven molecular design and rapid synthesis in overcoming resistance to single-target therapies.

We have developed specialized screening sets focused on serine proteases to support drug discovery projects targeting these critical enzymes. The collection comprises over 18,000 compounds, designed around protease substrate specificity and catalytic triad features. Additionally, assay-ready pre-plated subsets are available, ensuring structural diversity and facilitating immediate use in high-throughput screening.

The Library includes over 18,300 small molecules targeting adenosine-related targets, histamine receptors, and other neurodegenerative pathways. Designed through advanced cheminformatics selection, it offers structural diversity and biological relevance for CNS and neuroinflammation research.

Explore our meticulously selected Screening Set of 500 screening compounds, each structurally similar to FDA-approved drugs known for effectively treating various diseases. These compounds are predicted to exhibit desirable pharmacological properties, such as bioavailability, target specificity and safety. Thus, our collection of approved drug analogs can not only provide novel drug candidates but also redirect the applicability of existing compounds for unmet medical needs.